Processes and intermediates for the manufacture of tofacitinib
The process for manufacturing tofacitinib reduces N-methyl impurities and enhances yield by using cyanoacetic acid, a carbodiimide coupling agent, and citric acid in controlled solvent conditions, achieving high-purity tofacitinib suitable for industrial production.
Patent Information
- Application Number
- JP2022525786
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-31
- Filing Date
- 2020-10-28
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-10-28
AI Technical Summary
Existing processes for manufacturing tofacitinib suffer from yield losses due to alkali metal salt formation, hygroscopicity of the free base, and the formation of N-methyl impurities, making it difficult to achieve high purity and quantitative yield suitable for industrial scale-up.
A process involving the use of cyanoacetic acid, a carbodiimide coupling agent, and citric acid in specific solvents and conditions to minimize N-methyl impurities, along with hydrogenation under normal pressure to reduce dihydro impurities, and the use of ammonia to avoid alkali metal salt formation.
The process achieves high-purity tofacitinib with low synthesis cost and suitability for industrial scale-up, minimizing N-methyl and dihydro impurities, thereby improving yield and purity.
Smart Images

Figure 0007577743000001 
Figure 0007577743000002 
Figure 0007577743000003
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates generally to the field of process chemistry, and in particular to a process for the manufacture of tofacitinib that reduces the formation of N-methyl impurities. The present invention also relates to novel intermediates used in the process for the manufacture of tofacitinib.
[0002] 2. Background of the Invention 3-[(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile, commonly known as tofacitinib, is a member of the Janus kinase (JAK) inhibitor class and is indicated for the treatment of moderate to severe rheumatoid arthritis and moderate to severe ulcerative colitis. Xeljanz (Registered trademark )of It is sold commercially under the trade name.
[0003] Tofacitinib is a compound of formula I
[0004] [ka]
[0005] and its monocitrate salt has been reported and disclosed in Indian Patent No. 241773, but without giving any details about the stereochemistry of tofacitinib. Indian Patent Application No. 737 / MUMNP / 2011 discloses the preparation of chiral tofacitinib by reacting 4-chloro-pyrrolopyrimidine with the tartrate salt of (3R,4R)-1-benzyl-N,4-dimethyl-piperidin-3-amine, as shown diagrammatically below.
[0006] [ka]
[0007] The coupling of 4-chloro-pyrrolopyrimidine with the tartrate salt of (3R,4R)-1-benzyl-N,4-dimethyl-piperidin-3-amine gave a yield of 54% and the reaction time was about 90 hours, making it difficult to scale up industrially.
[0008] Alternatively, debenzylation of (3R,4R)-(1-benzyl-4-methyl-piperidin-3-yl)-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine is carried out using 20% palladium on carbon. The reported reaction time is 2 days. Furthermore, purification of methyl-((3R,4R)-4-methyl-piperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine requires flash chromatography.
[0009] Indian Patent Application No. 270 / DELNP / 2008 discloses a process for preparing tofacitinib by reacting bis-(3R,4R)-(1-benzyl-4-methyl-piperidin-3-yl)-methylamine di-p-toluoyl-L-tartaric acid with 4-chloro-7-(4-methyl-benzenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidine in the presence of potassium carbonate and water at 95-105° C. The coupled product was isolated in acetonitrile and detosylated in water using sodium hydroxide as base to form [(3R,4R)-1-benzyl-4-methyl-piperidin-3-yl]-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine.
[0010] Also, debenzylation was performed in a water-IPA mixture using 20% palladium hydroxide on carbon in the presence of acetic acid, and methyl-[(3R,4R)-4-methyl-piperidin-3-yl]-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine was isolated. Furthermore, tofacitinib was prepared by reacting methyl-[(3R,4R)-4-methyl-piperidin-3-yl]-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine with ethyl cyanoacetate in the presence of triethylamine.
[0011] Although the '270 application describes the detosylation of (1-benzyl-4-methyl-piperidin-3-yl)-methyl-[7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine in an aqueous solvent, the inventors have confirmed that the reaction does not occur substantially in aqueous media. Therefore, it is necessary to provide a suitable solvent for the reaction to occur smoothly and produce pure [(3R,4R)-1-benzyl-4-methyl-piperidin-3-yl]-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine.
[0012] [ka]
[0013] In addition, the isolation of the free base [(3R,4R)-1-benzyl-4-methyl-piperidin-3-yl]-methyl-[7-(4-methyl-benzenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine has a major problem of yield loss due to many reasons. Since the pH is adjusted using hydroxides such as sodium hydroxide, the sodium salt of [(3R,4R)-1-benzyl-4-methyl-piperidin-3-yl]-methyl-[7-(4-methyl-benzenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine is formed, which migrates to the aqueous layer, and thus there is a yield loss in the isolation of the free base. In addition, the free base is highly hygroscopic in nature, and absorbs water during filtration, resulting in an oily top layer, making it difficult to isolate the free base solid.
[0014] Therefore, there is a need for an alternative and improved process that avoids yield losses due to alkali metal salt formation and provides isolation of solid salts that give highly pure tofacitinib in quantitative yield.
[0015] Org.Process Res.Dev.2014,18(12),1714-1720 describes the detosylation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)methyl-(7-tosylpyrrolo[2,3-d]pyrimidin-4-yl)amine in alcohol solvent. In the reaction using methanol as the solvent, the reaction mass was cooled and directly filtered without distillation to give (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine with 96% purity.
[0016] [ka]
[0017] However, it has been determined that the actual crude reaction in methanol results in the formation of up to 6% of the N-methyl impurity shown in the structure above, which is difficult to remove and is carried over into the final product, tofacitinib citrate.
[0018] Therefore, there is a need to develop an alternative process that reduces the formation of the N-methyl impurity and provides high purity (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amine. Summary of the Invention
[0019] To overcome the above drawbacks of the prior art, the present invention provides an industrially viable process for the preparation of high purity tofacitinib, which has low synthesis cost, high yield, is environmentally friendly and suitable for industrial scale-up.
[0020] The present invention provides a process that reduces the formation of N-methyl impurities during the manufacture of tofacitinib.
[0021] In one aspect of the present invention there is provided an improved process for the preparation of tofacitinib (I), comprising:
[0022] [ka]
[0023] The process is as follows: 0.2-1.2 molar equivalents of cyanoacetic acid is added to the compound of formula (II-S),
[0024] [ka]
[0025] then adding a carbodiimide coupling agent of formula (III);
[0026] [ka]
[0027] Optionally, reacting the tofacitinib base with citric acid. A process is provided that includes:
[0028] In another aspect of the present invention, there is provided a process for preparing a compound of formula (II-S).
[0029] These and other aspects of the present invention may be more readily understood by reference to the following detailed description of exemplary embodiments of the invention and the examples included therein.
[0030] Detailed Description of the Invention The present invention provides a process for the production of highly pure tofacitinib by reducing the formation of N-methyl impurity.
[0031] In one embodiment, the present invention provides a process for the preparation of tofacitinib of formula (I) and salts thereof, comprising the following steps: (a) adding 0.2-1.2 molar equivalents of cyanoacetic acid to a compound of formula (II-S);
[0032] [ka]
[0033] (b) reacting the reaction mixture with a carbodiimide coupling agent of formula (III) (or a hydrogen halide or alkyl halide addition salt thereof)
[0034] [ka]
[0035] (c) optionally reacting the formed tofacitinib base with citric acid; wherein R is selected from cyclohexyl, isopropyl, ethyl, and 3-dimethylaminopropyl, wherein the R substituents of formula (III) can both be the same or a combination of the above groups. The present invention provides a process including:
[0036] In the process, step (a) is carried out at room temperature and the reaction is carried out in a suitable solvent, which can be, but is not limited to, aprotic solvents, esters, ethers, hydrocarbons, halogenated solvents and ketones.
[0037] For example, the aprotic solvent used is preferably acetonitrile. Esters may include, but are not limited to, ethyl acetate and butyl acetate. Ethers may include, but are not limited to, tetrahydrofuran (THF), methyl tert-butyl ether (MTBE) and di-isopropyl ether (DIPE). Hydrocarbon solvents may include, but are not limited to, toluene, xylene and cyclohexane. Halogenated hydrocarbons may include, but are not limited to, methylene dichloride (MDC), chloroform, 1,2-dichloroethane and chlorobenzene. Ketone solvents may include, but are not limited to, acetone and methyl isobutyl ketone (MIBK).
[0038] The carbodiimide coupling agent used in stage (ii) of the process is dicyclohexyl Carbodiimide , 1-ethyl-3 - These may include, but are not limited to, (3-dimethylaminopropyl)carbodiimide and N,N'-diisopropylcarbodiimide.
[0039] The reaction may be carried out in the presence of a coupling agent, such as hydroxybenzotriazole (HOBt), N-hydroxy-5-norbornene-endo-2,3-dicarboximide (HONB), N-hydroxysuccinimide (HOSu), hydroxy-7-azabenzotriazole (HOAt), O-(1H-benzotriazol-1-yl)-tetramethyluronium hexafluorophosphate, to( Examples of suitable fluorochemicals include, but are not limited to, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (HBTU) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU).
[0040] The reaction is carried out at 0-40°C, preferably 15-20°C.
[0041] The tofacitinib base formed in step (c) can be isolated or can be converted in situ to tofacitinib citrate by reacting with citric acid.
[0042] In another embodiment, the present invention provides a process for the preparation of a compound of formula (II-S), comprising the steps of: (ia) reacting a compound of formula (VI) with a compound of formula (VII) in the presence of a suitable alkali to form a compound of formula (V);
[0043] [ka]
[0044] (iia) reacting a compound of formula (V) with a suitable alkali metal hydroxide, said reaction being carried out in a solvent system as defined above, to form a compound of formula (IV).
[0045] [ka]
[0046] (iiia) hydrogenating a compound of formula (IV) using a suitable metal catalyst at pH 3-5 to form a compound of formula (II);
[0047] [ka]
[0048] (iva) without isolating the compound of formula (II), adjusting the pH of the reaction mass with an organic base such as ammonia, extracting compound (II) from the reaction mass with a suitable solvent and adding cyanoacetic acid to form and isolate the cyanoacetate salt of formula (II-S). The present invention provides a process including:
[0049] The organic base used may be selected from, but is not limited to, ammonia, mono-, di- or trialkylamines such as methylamine, ethylenediamine, dimethylamine, triethylamine and diisopropylethylamine, aromatic amines such as pyridine and N,N-dimethylaniline. The preferred base is ammonia. The solvents used for extraction and cyanoacetate formation may include, but are not limited to, water-immiscible solvents such as higher alcohols such as 1-butanol, hydrocarbons (toluene, cyclohexane), esters (ethyl acetate, butyl acetate) and ethers (diisopropyl ether, methyl tertiary butyl ether).
[0050] The salts are characterized by NMR.
[0051] 1H NMR (300 MHz, D2O): 7.747 (1H), 6.871-6.861 (1H), 6.168 (1H), 4.420 (1H), 3.463-3.387 (1H), 3.320-3.182 (3H), 3.092-3.031 (2H), 2.909 (3H), 2.015 (1H), 1.879-1.819 (1H), 1.554-1.505 (1H), 0.784-0.761 (3H).
[0052] 13 C APT (300 MHz, D6-DMSO): 166.04 (C), 156.91 (C), 152.13 (C), 150.95 (CH), 121.57 (CH), 118.86 (C), 102.72 (C), 102.01 (CH), 52.67 (CH3), 41.14 (CH2), 38.68 (CH2), 34.23 (CH), 30.18 (CH), 28.89 (CH2), 27.30 (CH2), 12.81 (CH3).
[0053] Compound VI used in step (ia) of the process is a salt with a suitable acid selected from hydrochloric acid, tartaric acid, ditoluoyltartaric acid, acetic acid and sulfuric acid. The alkali used in step (ia) is an inorganic base such as an alkali metal carbonate, preferably selected from potassium carbonate and sodium carbonate.
[0054] The reaction is carried out at 80-100°C, preferably 85-95°C, especially 90-95°C.
[0055] The alkali metal hydroxides used in step (iia) of the process may include, but are not limited to, lithium hydroxide, sodium hydroxide and potassium hydroxide.
[0056] It has been determined by the inventors that the reaction does not proceed at all when carried out in water or in a substantially aqueous solvent.
[0057] Therefore, alcohol-water solvent systems were tried using various alcohol solvents such as methanol, ethanol or isopropanol. It has been observed that N-alkyl impurities are formed in the reaction depending on the solvent used. The methanol-water solvent system was found to work better than the other alcohol solvents.
[0058] In a typical course of the reaction in step (iia) using methanol solvent, about 6-8% of an N-methyl impurity is formed, which is represented by the following structure:
[0059] [ka]
[0060] The impurity is confirmed by LCMS and NMR.
[0061] LCMS showed that the molecular ion [M+H]+ was detected at (350 m / z), which corresponds to a molecular weight of (349).
[0062] Proton NMR shows a singlet at δ=3.7, corresponding to the N-7 methyl group.
[0063] The solvent system used in step (iia) is methanol and water. It has been determined that the ratio of methanol to water plays an important role in the formation of the N-methyl impurity.
[0064] The reaction is studied with various ratios of methanol to water. The table below shows the effect of methanol to water ratio on the formation of N-methyl impurity.
[0065] [Table 1]
[0066] From Table 1, it is clear that the best results are obtained when the methanol:water ratio is 4:1. The reaction is carried out at 30-65°C, preferably 35-45°C.
[0067] The metal catalyst used in step (iiia) may include, but is not limited to, palladium(0), Pd on carbon, Pd(OH)2, palladium acetate, platinum oxide, platinum black, Raney nickel, etc. Prior to adding the metal catalyst, the pH of the reaction mixture is adjusted to 3-5, preferably 3.5-4.5, using a suitable acid.
[0068] Suitable acids for use in step (iiia) may preferably include, but are not limited to, hydrochloric acid, acetic acid and sulfuric acid.
[0069] The reaction is carried out at 25-60°C, preferably 45-55°C.
[0070] The reaction can be carried out under hydrogen pressure in an inert atmosphere, although the reaction proceeds satisfactorily under ambient conditions, which is achieved by purging the reaction mass with hydrogen gas.
[0071] An additional benefit of purging with hydrogen is that it minimizes the dihydro impurity in the reaction, which can be represented by the following structure:
[0072] [ka]
[0073] The formation of this dihydro impurity during hydrogenation under pressure has been reported in the literature and confirmed by the inventors. At least 1% of this impurity is formed in the reaction and is carried over to the next step. This impurity is difficult to remove in the next step, requiring extra purification steps to remove it, which ultimately affects the yield of the final product.
[0074] When hydrogen purging is performed and the reaction is carried out under atmospheric conditions, the formation of the dihydro impurity is minimized to less than 0.5%, which can be easily controlled with one purification step in the next step.
[0075] The ammonia used in step (iva) of the process is aqueous ammonia, gaseous ammonia or liquid ammonia. By using ammonia instead of an alkali metal hydroxide, yield losses due to the formation of alkali metal salts are avoided.
[0076] Step (iva) is carried out in a suitable water-immiscible solvent such as higher alcohols such as 1-butanol, hydrocarbons such as toluene and cyclohexane, esters such as ethyl acetate and butyl acetate, and ethers such as diisopropyl ether and methyl tertiary butyl ether. EXAMPLES
[0077] Specific embodiments of the present invention will now be demonstrated by reference to the following examples, which are merely disclosed to illustrate the present invention and should not be construed as limiting the scope of the present invention in any manner.
[0078] Example 1 Preparation of N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7-(p-tolylsulfonyl)pyrrole[2,3-d]pyrimidin-4-amine (3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride (100 g) was charged in water (100 ml) and the reaction mixture was stirred. Potassium carbonate (376 gm) was charged in lots to the mixture. The mixture was stirred for 15-20 minutes. 4-Chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine (132 gm) was charged to the reaction mass and the temperature was increased to 90-95°C. The mass was stirred at 90-95°C for 18-19 hours. The mass was cooled to 30-35°C and the mass was further stirred for 1-1.5 hours. The mass was filtered and sucked dry. MDC (1000 ml) was charged to the compound and stirred to get a clear solution. The layers were extracted with water (500 ml x 2). The layers were separated and MDC was distilled off in air. Acetonitrile (50 ml) was charged and the temperature was increased to 60-65°C and stirred for 1-1.5 hours. The slurry was cooled to 30-35°C and stirred for 1 hour, then filtered and dried under vacuum for 6-7 hours to isolate N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7-(p-tolylsulfonyl)pyrrolo[2,3-d]pyrimidin-4-amine (155 gm). Purity: 99.28%
[0079] Example 2 Preparation of N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7-(p-tolylsulfonyl)pyrrolo[2,3-d]pyrimidin-4-amine (100 g) obtained in Example 1 was added to methanol (400 ml) and the mixture was stirred for 15-20 minutes. A 6M solution of potassium hydroxide (100 ml) was prepared separately and slowly added to the reaction mixture while maintaining the temperature. The mass was stirred for 1-1.5 hours and the temperature was allowed to rise to 40°C. The mass was further stirred at 40-45°C for 19-20 hours. After cooling to 30-35°C, water (500 ml) was added to the reaction mass and stirred for 1-1.5 hours. The mass was filtered and the product was washed with water (100 ml). 5% aqueous sodium bicarbonate solution (500 ml) was charged to the wet solid and the mass was stirred for 1-1.5 hours and filtered. The wet solid was suspended in water (500 ml) at 60-65°C and hot filtered. The wet solid was charged in acetonitrile (300 ml) and stirred for 1-1.5 hours. The mass was filtered and dried under vacuum at 50-55°C for 6-7 hours. N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (65 gm) was isolated. Purity:97.13%
[0080] Example 3 N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine cyanoacetate N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (100 g) obtained in Example 2 was taken in a mixture of water (450 ml) and acetic acid (89.45 gm). The mixture was stirred for 50-60 minutes, filtered and washed with water (50 ml). 5% pd / C (20 gm) was taken in the filtrate and the mixture was stirred under hydrogen at 40-50°C for 18-24 hours in an inert atmosphere. The mass was cooled to 20-25°C, filtered and the pH was adjusted to 9 with ammonia. The temperature was increased to 30-35°C and n-butanol (500 ml) was taken. The layers were separated and cyanoacetic acid (25.36 gm) was taken in the organic layer. The mass was stirred and the solvent was distilled off under vacuum. The mass was cooled to 30-35° C. and acetonitrile (300 ml) was charged. The temperature was increased to 55-60° C. and the mass was cooled to 30-35° C., stirred for 1 hour, then stirred for 1-1.5 hours, filtered and dried under vacuum at 50-55° C. for 7-8 hours. N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine cyanoacetate (86.5 gm) was isolated. Purity: 99.50%
[0081] Example 4 N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine cyanoacetate N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (500 g) obtained in Example 2 was charged in a mixture of water (450 ml) and the pH of the reaction mixture was adjusted to 3.5-4.5 using hydrochloric acid at room temperature. The reaction mixture was stirred for 30-60 minutes. The mass was filtered and washed with water. 5% pd / C (10 gm) was charged into the filtrate. Hydrogen gas was purged into the mass and the temperature was increased to 40-45°C. The mass was stirred at 40-45°C for 12-18 hours. The mass was cooled to 20-25°C, filtered and the pH was adjusted to 9 with ammonia. The temperature was increased to 30-35°C and n-butanol (500 ml) was charged. The layers were separated and the organic layer was charged with cyanoacetic acid (25.36 gm). The mass was stirred and the solvent was removed under vacuum. The mass was cooled to 30-35°C and acetonitrile (300 ml) was charged. The temperature was increased to 55-60°C and the mass was stirred for 1-1.5 hours. The mass was cooled to 30-35°C and stirred for 1 hour, then filtered and dried under vacuum at 50-55°C for 7-8 hours. N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine cyanoacetate (43.3 gm) was isolated. Purity: 99.50% N-Methyl impurity - 0.5%
[0082] Example 5 N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (100 g) obtained in Example 2 was taken in water (450 ml) and the pH of the reaction mixture was adjusted to 3.5-4.5 using hydrochloric acid at room temperature. The reaction mixture was stirred for 30-60 minutes. The mass was filtered and washed with water. 5% pd / C (10 gm) was charged into the filtrate. Hydrogen gas was purged into the mass and the temperature was increased to 45-50°C. The mass was stirred at 45-50°C for 10-12 hours. The mass was cooled to 30-35°C, filtered and cooled to 15 to 20°C. The pH of the reaction mass was adjusted to 9 with ammonia. The temperature was increased to 30-35°C and n-butanol (500 ml) was charged. The mass was stirred and the layers were separated. The organic layer was evaporated under vacuum and the mass was cooled. Acetonitrile (300 ml) was charged to the reaction mass and the temperature was increased to 60-65°C. The mass was stirred for 1-1.5 hours. The mass was cooled to 25-30°C and stirred for 2-3 hours. The mass was filtered and washed with acetonitrile (100 ml). The product was sucked dry and N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine was isolated as a wet solid. N-Methyl impurity: 1% Dihydro impurity - not detected
[0083] Example 6 Purification of N-methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Acetonitrile (100 ml) was added to N-methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine obtained in Example 5 at 30-35° C. The temperature of the reaction mixture was increased to 60-65° C. and the mixture was stirred for 1-1.5 hours. The mass was cooled to 25-30° C. and stirred for 2-3 hours. The mass was filtered and washed with acetonitrile (100 ml). N-methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine was isolated as a wet solid. N-Methyl impurity: 0.5% Dihydro impurity - not detected
[0084] Example 7 N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine cyanoacetate Acetonitrile (200 ml) was charged into N-methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine obtained in Example 6 at 30-35°C. The reaction mixture was stirred for 1-1.5 hours. Cyanoacetic acid solution (prepared by dissolving 25.36 gm of cyanoacetic acid in 100 ml of acetonitrile) was charged into the above reaction mixture. The temperature was increased to 60-65°C and the mass was stirred for 1.5-2 hours. The mixture was cooled to 25-30°C and stirred for 2-3 hours. The mass was filtered, washed with acetonitrile (100 ml) and sucked dry. The product was dried under vacuum for 5-6 hours. N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine cyanoacetate (79 gm) was isolated (80% yield). N-Methyl impurity – not detected Dihydro impurity - not detected
[0085] Example 8 Tofacitinib Citrate N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine cyanoacetate (100 gm) obtained from Example 4 was taken in acetonitrile (400 ml). Cyanoacetic acid (12.87 g) was charged to the reaction mixture and the reaction mass was cooled to 15-20°C. Dicyclohexylcarbodiimide ( DCC ) A solution of (93.66 gm) in acetonitrile (300 ml) was charged at 15-20° C. and the reaction mass was stirred at the same temperature for 1-1.5 hours. After the reaction was completed, aqueous ammonia (30 ml) was added to the reaction mass and stirred for 1-1.5 hours. The reaction mass was then filtered and washed with acetonitrile (200 ml). The filtrate was decolorized using carbon treatment and purified. Round-bottom flask ( RBF ) The temperature was increased to 70-75°C and a solution of citric acid (140 gm) in water (150 ml) was added to the reaction mass. The mass was stirred for 1-1.5 hours. The mass was cooled to 25-30°C and the mass was further stirred for 2-2.5 hours. The mass was filtered and the precipitate was taken in acetonitrile (1470 ml) and water (630 ml) was added to the solution. The temperature was increased to 70-75°C and stirred for 2-2.5 hours. The reaction mass was cooled to 20-30°C and stirred at this temperature for 1-1.5 hours. The mass was filtered and the product was washed with acetonitrile (150 ml) and dried under vacuum at 65-70°C for 7-8 hours. Tofacitinib citrate (125 g) was isolated as a white to off-white powder. Purity: 99.90% N-Methyl impurity – not detected Dihydro impurity - not detected
Claims
1. A process for the preparation of tofacitinib of formula (I) and salts thereof, comprising: 【Chemistry 1】 The following steps: (a) adding 0.2-1.2 molar equivalents of cyanoacetic acid to a compound of formula (II-S); 【Chemistry 2】 (b) reacting the reaction mixture with a carbodiimide of formula (III) or its hydrogen halide or alkyl halide addition salt in the presence of a coupling agent at 0-40° C.; 【Chemistry 3】 (wherein R is selected from cyclohexyl, isopropyl, ethyl, and 3-dimethylaminopropyl). The process includes:
2. 2. The process of claim 1, wherein step (a) is carried out at room temperature.
3. 2. The process of claim 1, wherein step (a) is carried out in a solvent selected from the group consisting of aprotic solvents, hydrocarbons, esters, ethers, halogenated solvents and ketones.
4. 2. The process of claim 1, wherein the carbodiimide of formula (III) is selected from the group comprising dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N,N'-diisopropylcarbodiimide.
5. 2. The process of claim 1, wherein the coupling agent is selected from the group comprising hydroxybenzotriazole (HOBt), N-hydroxy-5-norbornene-endo-2,3-dicarboximide (HONB), N-hydroxysuccinimide (HOSu), hydroxy-7-azabenzotriazole (HOAt), O-(1H-benzotriazol-1-yl)-tetramethyluronium hexafluorophosphate (HBTU) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU).
6. 2. The process of claim 1, wherein the tofacitinib formed in step (b) is reacted with citric acid to obtain tofacitinib citrate.
7. A process for the preparation of a compound of formula (II-S), comprising: 【Chemistry 4】 The following steps: (ia) reacting a compound of formula (VI) with a compound of formula (VII) in the presence of an inorganic base at 80-100° C. to form a compound of formula (V); 【Chemistry 5】 (iia) reacting a compound of formula (V) with an alkali metal hydroxide, wherein the reaction is carried out in a solvent system at 30-65° C. to form a compound of formula (IV); 【Chemistry 6】 (iiia) hydrogenating the compound of formula (IV) using a metal catalyst at 25-60° C. under pH 3-5 to form a compound of formula (II); 【Chemistry 7】 (iva) adjusting the pH of the reaction mass with an organic base; (va) extracting the compound of formula (II) from the reaction mass using a solvent; (via) adding cyanoacetic acid to form a compound of formula (II-S); The process includes:
8. 8. The process of claim 7, wherein compound VI is a salt with an acid selected from the group consisting of hydrochloric acid, tartaric acid, ditoluoyltartaric acid, acetic acid and sulfuric acid.
9. 8. The process of claim 7, wherein the organic base is an alkali metal carbonate.
10. 8. The process of claim 7, wherein the alkali metal hydroxide is selected from the group consisting of lithium hydroxide, sodium hydroxide and potassium hydroxide.
11. 8. The process of claim 7, wherein the solvent system is a mixture of water and an alcohol selected from the group consisting of methanol, ethanol and isopropanol.
12. 12. The process of claim 11, wherein the solvent system is a mixture of water and methanol.
13. The metal catalyst is palladium(0), Pd on carbon, Pd(OH) 2 8. The process of claim 7, wherein the catalyst is selected from the group consisting of palladium acetate, platinum oxide, platinum black and Raney nickel.
14. 8. The process of claim 7, wherein the pH in step (iiia) is adjusted using an acid selected from the group consisting of hydrochloric acid, acetic acid and sulfuric acid.
15. 8. The process of claim 7, wherein the organic base is selected from the group consisting of ammonia, mono-, di- and trialkylamines.
16. 16. The process of claim 15, wherein the organic base is ammonia selected from the group consisting of aqueous ammonia, gaseous ammonia and liquid ammonia.
17. 8. The process of claim 7, wherein the solvent in step (va) is a water-immiscible solvent.
18. 18. The process of claim 17, wherein the solvent is selected from the group comprising alcohols, hydrocarbons, esters and ethers.
19. 8. The process of claim 7, wherein step (iiia) is carried out under atmospheric pressure.
20. 20. The process of claim 19, wherein hydrogen gas is purged into the reaction mixture.
Citation Information
Patent Citations
Preparation method of medicinal crystal form tofacitinib citrate
CN104530053A
Synthesis method of JAK inhibitor tofacitinib
CN105693728A
Industrial production method of citric acid tofacitinib
CN107793418A
Tofacitinib citrate refining method
CN108358929A
Refining method of tofacitinib citrate
CN108794491A
